Autophagy inhibition suppresses the tumorigenic potential of cancer stem cell enriched side population in bladder cancer

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 11, 2014, Pages 2073-2086

  Ojha, Rani ^a   Jha, Vivekanand ^a   Singh, Shrawan Kumar ^a   Bhattacharyya, Shalmoli ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Autophagy; Bladder cancer; Cancer stem cell; Side population; T24; UM UC 3

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; GEMCITABINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ARTICLE; AUTOPHAGY; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; GENE EXPRESSION;

EID: 84908389410     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.07.007     Document Type: Article

References (40)

1. Dean M., Fojo T., Bates S. Tumor stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
2. Beck B., Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013, 10:727-738.
3. Kondo T., Setoguchi T., Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:781-786.
4. Zhou S., Schuetz J.D., Bunting K.D., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7:1028-1034.
5. Sengupta N., Siddiqui E., Mumtaz F.H. Cancers of the bladder. J. R. Soc. Health 2004, 124:228-229.
6. Dickstein R.J., Nitti G., Dinney C.P., Davies B.R., Kamat A.M., McConkey D.J. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol. Ther. 2012, 13:1325-1338.
7. Ojha R., Singh S.K., Bhattacharyya S., et al. Inhibition of grade dependent autophagy in urothelial carcinoma increases cell death under nutritional limiting condition and potentiates the cytotoxicity of chemotherapeutic agent. J. Urol. 2014 Jan 15, (pii: S0022-5347 (14) 00017-2, [Epub ahead of print]). 10.1016/j. juro.2014.01.006.
8. Qu X., Yu J., Bhagat G., et al. Promotion of tumorigenesis by heterozygous disruption of the Beclin 1 autophagy gene. J. Clin. Invest. 2003, 112:1809-1820.
9. Sun K., Deng W., Zhang S., Cai N., Jiao S., Song J., Wei L. Paradoxical roles of autophagy in different stages of tumorigenesis: protector for normal or cancer cells. Cell Biosci. 2013, 3:35.
10. Yang Z.J., Chee C.E., Huang S., Sinicrope F.A. The role of autophagy in cancer: therapeutic implications. Mol. Cancer Ther. 2011, 9:1533-1541.
11. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
12. Harris A.L. Hypoxia: a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
13. Loges S., Schmidt T., Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010, 1:12-25.
14. Azad M.B., Chen Y., Gibson S.B. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid. Redox Signal. 2009, 11:777-790.
15. Semenza G.L. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim. Biophys. Acta 2011, 1813:1263-1268.
16. Shi X., Zhang Y., Zheng J., Pan J. Reactive oxygen species in cancer stem cells. Antioxid. Redox Signal. 2012, 16:1215-1228.
17. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996, 183:1797-1806.
18. Cao L., Zhou Y., Zhai B., et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011, 11:1-11.
19. Zhu Y.Y., Machleder E.M., Chenchik A., Li R., Siebert P.D. Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction. Biotechniques 2001, 30:892-897.
20. Eruslanov E., Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol. Biol. 2010, 594:57-72.
21. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11154-11159.
22. Telford W.G., Bradford J., Godfrey W., Robert Robey W., Bates S.E. Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem Cells 2007, 25:1029-1036.
23. Naor D., Nedvetzki S., Golan I., Melnik L., Faitelson Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 2002, 39:527-579.
24. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
25. Zhou S., Morris J.J., Barnes Y., Lan L., Schuetz J.D., Sorrentino B.P. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12339-12344.
26. Nishiyama K., Shirahama T., Yoshimura A., et al. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer 1993, 71:3611-3619.
27. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
28. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
29. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
30. Evers P., Lee P.P., DeMarco J., et al. Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer 2010, 387:1-7.
31. Amaravadi R.K., Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res. 2007, 13:7271-7279.
32. Wu Y.T., Tan H.L., Shui G., Bauvy C., et al. Dual role of 3-methyl adenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J. Biol. Chem. 2010, 285:10850-10861.
33. Singh V.P., Saluja A.K., Bhagat L., et al. Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis. J. Clin. Invest. 2001, 108:1387-1395.
34. Scherz-Shouval R., Shvets E., Fass E., Shorer H., Gil L., Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007, 26:1749-1760.
35. Jaber N., Dou Z., Chen J.S., et al. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc. Natl. Acad. Sci. 2012, 109:2003-2008.
36. Mizushima N., Yoshimori T., Levine B. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
37. Boya P., González-Polo R.A., Casares N., et al. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 2005, 25:1025-1040.
38. Dalby K.N., Tekedereli I., Lopez-Berestein G., Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010, 6:322-329.
39. Mergny M.D., Maiuri M.C., Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 2010, 29:1717-1719.
40. Amaravadi R.K., Yu D., Lum J.J., et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest. 2007, 117:326-336.